318 related articles for article (PubMed ID: 28652707)
1. Development of new promising antimetabolite, DFP-11207 with self-controlled toxicity in rodents.
Fukushima M; Iizuka K; Jin C; Zhang C; Hong M; Eshima K
Drug Des Devel Ther; 2017; 11():1693-1705. PubMed ID: 28652707
[TBL] [Abstract][Full Text] [Related]
2. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators.
Shirasaka T; Shimamato Y; Ohshimo H; Yamaguchi M; Kato T; Yonekura K; Fukushima M
Anticancer Drugs; 1996 Jul; 7(5):548-57. PubMed ID: 8862723
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of DFP-11207, a novel oral fluoropyrimidine with reasonable AUC and low C
Ajani JA; Javle M; Eng C; Fogelman D; Smith J; Anderson B; Zhang C; Iizuka K
Invest New Drugs; 2020 Dec; 38(6):1763-1773. PubMed ID: 32377978
[TBL] [Abstract][Full Text] [Related]
4. The upregulation of dihydropyrimidine dehydrogenase in liver is involved in acquired resistance to 5-fluorouracil.
Li LH; Dong H; Zhao F; Tang J; Chen X; Ding J; Men HT; Luo WX; Du Y; Ge J; Tan BX; Cao D; Liu JY
Eur J Cancer; 2013 May; 49(7):1752-60. PubMed ID: 23313143
[TBL] [Abstract][Full Text] [Related]
5. [Invention of a tumor-selective 5-fluorouracil derivative named S-1 by biochemical modulation of 5-fluorouracil].
Shirasaka T; Shimamoto Y; Kato T; Fukushima M
Gan To Kagaku Ryoho; 1998 Feb; 25(3):371-84. PubMed ID: 9492831
[TBL] [Abstract][Full Text] [Related]
6. Impact of 5-fluorouracil metabolizing enzymes on chemotherapy in patients with resectable colorectal cancer.
Ochiai T; Umeki M; Miyake H; Iida T; Okumura M; Ohno K; Sakamoto M; Miyoshi N; Takahashi M; Tsumura H; Tokunaga Y; Naitou H; Fukui T
Oncol Rep; 2014 Sep; 32(3):887-92. PubMed ID: 24994673
[TBL] [Abstract][Full Text] [Related]
7. Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies.
Chu QS; Hammond LA; Schwartz G; Ochoa L; Rha SY; Denis L; Molpus K; Roedig B; Letrent SP; Damle B; DeCillis AP; Rowinsky EK
Clin Cancer Res; 2004 Aug; 10(15):4913-21. PubMed ID: 15297391
[TBL] [Abstract][Full Text] [Related]
8. Anticancer activity and toxicity of S-1, an oral combination of tegafur and two biochemical modulators, compared with continuous i.v. infusion of 5-fluorouracil.
Fukushima M; Shimamoto Y; Kato T; Uchida J; Yonekura R; Ohshimo H; Shirasaka T
Anticancer Drugs; 1998 Oct; 9(9):817-23. PubMed ID: 9840729
[TBL] [Abstract][Full Text] [Related]
9. A possible mechanism of eighteen patient deaths caused by interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs.
Okuda H; Ogura K; Kato A; Takubo H; Watabe T
J Pharmacol Exp Ther; 1998 Nov; 287(2):791-9. PubMed ID: 9808711
[TBL] [Abstract][Full Text] [Related]
10. Correlations between antitumor activities of fluoropyrimidines and DPD activity in lung tumor xenografts.
Takechi T; Okabe H; Ikeda K; Fujioka A; Nakagawa F; Ohshimo H; Kitazato K; Fukushima M
Oncol Rep; 2005 Jul; 14(1):33-9. PubMed ID: 15944764
[TBL] [Abstract][Full Text] [Related]
11. Drug delivery of oral anti-cancer fluoropyrimidine agents.
Miura K; Shima H; Takebe N; Rhie J; Satoh K; Kakugawa Y; Satoh M; Kinouchi M; Yamamoto K; Hasegawa Y; Kawai M; Kanazawa K; Fujiya T; Unno M; Katakura R
Expert Opin Drug Deliv; 2017 Dec; 14(12):1355-1366. PubMed ID: 28379040
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of 5-fluorouracil metabolic enzyme genes in Dukes' stage B and C colorectal cancer patients treated with oral 5-fluorouracil-based adjuvant chemotherapy.
Yamada H; Iinuma H; Watanabe T
Oncol Rep; 2008 Mar; 19(3):729-35. PubMed ID: 18288408
[TBL] [Abstract][Full Text] [Related]
13. Increased cytotoxicity and decreased in vivo toxicity of FdUMP[10] relative to 5-FU.
Liu J; Skradis A; Kolar C; Kolath J; Anderson J; Lawson T; Talmadge J; Gmeiner WH
Nucleosides Nucleotides; 1999 Aug; 18(8):1789-802. PubMed ID: 10478484
[TBL] [Abstract][Full Text] [Related]
14. Effects of a bolus injection of 5-fluorouracil on dihydropyrimidine dehydrogenase activity in rats receiving continuous infusion of 5-fluorouracil.
Kobuchi S; Hayashi A; Taniguchi M; Ito Y; Tamura T; Sakaeda T
Cancer Chemother Pharmacol; 2016 Sep; 78(3):517-23. PubMed ID: 27417318
[TBL] [Abstract][Full Text] [Related]
15. Synergistic antitumor effect of combined 5-fluorouracil (5-FU) with 5-chloro-2,4-dihydroxypyridine on 5-FU-resistant gastric cancer cells: possible role of a dihydropyrimidine dehydrogenase-independent mechanism.
Sasaki E; Tominaga K; Kuwamura H; Watanabe T; Fujiwara Y; Oshitani N; Higuchi K; Arakawa T
J Gastroenterol; 2007 Oct; 42(10):816-22. PubMed ID: 17940834
[TBL] [Abstract][Full Text] [Related]
16. The significance of the expression of dihydropyrimidine dehydrogenase in prostate cancer.
Li Y; Mizutani Y; Shiraishi T; Nakamura T; Mikami K; Takaha N; Okihara K; Kawauchi A; Sakai T; Miki T
BJU Int; 2007 Mar; 99(3):663-8. PubMed ID: 17092280
[TBL] [Abstract][Full Text] [Related]
17. [Prediction of sensitivity to 5-fluorouracil (5-fu) by metabolic and target enzyme activities in colon cancer].
Yamada T; Tanaka N; Yokoi K; Ishikawa N; Seya T; Horiba K; Kanazawa Y; Shirakawa T; Ohkawa K; Kudoh H; Koizumi M; Yoshioka M; Shinji S; Yamashita K; Tajiri T
Gan To Kagaku Ryoho; 2006 Nov; 33(11):1603-9. PubMed ID: 17108726
[TBL] [Abstract][Full Text] [Related]
18. Enhanced 5-fluorouracil cytotoxicity in high cyclooxygenase-2 expressing colorectal cancer cells and xenografts induced by non-steroidal anti-inflammatory drugs via downregulation of dihydropyrimidine dehydrogenase.
Réti A; Pap E; Adleff V; Jeney A; Kralovánszky J; Budai B
Cancer Chemother Pharmacol; 2010 Jul; 66(2):219-27. PubMed ID: 19830428
[TBL] [Abstract][Full Text] [Related]
19. Pre-therapeutic assessment of plasma dihydrouracil/uracil ratio for predicting the pharmacokinetic parameters of 5-fluorouracil and tumor growth in a rat model of colorectal cancer.
Kobuchi S; Ito Y; Okada K; Imoto K; Kuwano S; Takada K
Biol Pharm Bull; 2013; 36(6):907-16. PubMed ID: 23575271
[TBL] [Abstract][Full Text] [Related]
20. A predictive biomarker for altered 5-fluorouracil pharmacokinetics following repeated administration in a rat model of colorectal cancer.
Kobuchi S; Kuwano S; Imoto K; Okada K; Nishimura A; Ito Y; Shibata N; Takada K
Biopharm Drug Dispos; 2013 Oct; 34(7):365-76. PubMed ID: 23836081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
